Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Approves Bylaw Amendment and Re-elects Directors
Summary
Alnylam Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders on May 8, 2025. Stockholders approved a Certificate of Amendment to the Company's Restated Certificate of Incorporation to allow for officer exculpation. They also re-elected four directors, approved the Second Amended and Restated 2018 Stock Incentive Plan, and ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2025.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement